Penumbra beats Q1 expectations, reaffirms 2025 outlook

Published 23/04/2025, 21:46
Penumbra beats Q1 expectations, reaffirms 2025 outlook

ALAMEDA, Calif. - Penumbra, Inc. (NYSE:PEN), a leading thrombectomy company, reported first-quarter earnings that surpassed analyst estimates, driving its stock up 1.5% in after-hours trading.

The medical device maker posted adjusted earnings per share of $0.83, exceeding the consensus estimate of $0.67. Revenue for the quarter reached $324.1 million, up 16.3% YoY and above the expected $315.62 million. U.S. Thrombectomy revenue, a key growth driver, surged 25% to $187.9 million compared to the same period last year.

Penumbra reaffirmed its full-year 2025 revenue guidance of $1.34 billion to $1.36 billion, which falls below the analyst consensus of $1.543 billion. However, the company raised its outlook for U.S. Thrombectomy franchise growth to 20-21% YoY, up from the previous 19-20% projection.

"Our strong first-quarter performance reflects the continued momentum in our thrombectomy business," said Adam Elsesser, Penumbra’s Chairman and CEO. "We’re particularly encouraged by the robust growth in our U.S. market, which positions us well for the rest of the year."

The company reported an improvement in gross margin to 66.6% from 65% in the prior-year quarter, citing favorable product mix and productivity enhancements. Penumbra expects further gross margin expansion of at least 100 basis points in 2025, to over 67% for the full year.

Operating income for the quarter was $40.4 million, representing a 12.4% operating margin. The company anticipates operating margin expansion to 13-14% of revenue for the full year 2025.

Penumbra’s international revenue decreased by 2.5%, or 0.1% in constant currency, while U.S. revenue grew by 22.5% compared to the first quarter of 2024.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.